HRP20170463T1 - Pripravci i postupci protiv cxcr1 - Google Patents
Pripravci i postupci protiv cxcr1 Download PDFInfo
- Publication number
- HRP20170463T1 HRP20170463T1 HRP20170463TT HRP20170463T HRP20170463T1 HR P20170463 T1 HRP20170463 T1 HR P20170463T1 HR P20170463T T HRP20170463T T HR P20170463TT HR P20170463 T HRP20170463 T HR P20170463T HR P20170463 T1 HRP20170463 T1 HR P20170463T1
- Authority
- HR
- Croatia
- Prior art keywords
- intended
- accordance
- stem cells
- cxcr1
- cxcr1 antagonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 13
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 13
- 210000000130 stem cell Anatomy 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 239000003080 antimitotic agent Substances 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical group CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- XJTXBUKLGQCZHC-UHFFFAOYSA-N Steganacin Natural products C1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC3C(=O)OCC3C(OC(C)=O)C2=CC2=C1OCO2 XJTXBUKLGQCZHC-UHFFFAOYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000000441 neoplastic stem cell Anatomy 0.000 claims 1
- 229950006344 nocodazole Drugs 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- 229960001237 podophyllotoxin Drugs 0.000 claims 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 1
- XJTXBUKLGQCZHC-GCKMJXCFSA-N steganacin Chemical compound C1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H]3C(=O)OC[C@H]3[C@H](OC(C)=O)C2=CC2=C1OCO2 XJTXBUKLGQCZHC-GCKMJXCFSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Claims (10)
1. Antagonist CXCR1, namijenjen upotrebi u postupku liječenja subjekta koji ima tumor, naznačen time što se postupak dodatno sastoji u primjeni kemoterapijskog sredstva.
2. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeni antagonist CXCR1 repertaksin ili derivat repertaksina.
3. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni antagonist CXCR1 sadrži protutijelo ili fragment protutijela.
4. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeno kemoterapijsko sredstvo antimitotsko sredstvo.
5. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što navedeno antimitotsko sredstvo se bira iz skupine koju čine: docetaksel, doksorubicin, paklitaksel, fluoruracil, vinkristin, vinblastin, nokodazol, kolhicin, podofilotoksin, steganacin i kombretastatin.
6. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što je navedeno antimitotsko sredstvo paklitaksel.
7. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni tumor sadrži matične stanice raka, koje se bira iz skupine koju čine: matične stanice raka prostate, matične stanice raka jajnika, matične stanice raka dojke, matične stanice raka kože, matične stanice raka velikih stanica pluća, matične stanice raka malih stanica pluća, te matične stanice adenokarcinoma jednjaka.
8. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je navedeni antagonist CXCR1 repertaksin, te što je navedeno kemoterapijsko sredstvo paklitaksel.
9. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je navedeni tumor rak dojke.
10. Antagonist CXCR1, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što navedeni rak dojke sadrži matične stanice raka dojke.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11345808P | 2008-11-11 | 2008-11-11 | |
| EP09826676.0A EP2356462B1 (en) | 2008-11-11 | 2009-11-11 | Anti-cxcr1 compositions and methods |
| PCT/US2009/064041 WO2010056753A1 (en) | 2008-11-11 | 2009-11-11 | Anti-cxcr1 compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170463T1 true HRP20170463T1 (hr) | 2017-05-19 |
Family
ID=42170302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170463TT HRP20170463T1 (hr) | 2008-11-11 | 2017-03-21 | Pripravci i postupci protiv cxcr1 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8940301B2 (hr) |
| EP (2) | EP3153862A1 (hr) |
| JP (3) | JP5716180B2 (hr) |
| KR (3) | KR20150065930A (hr) |
| CN (3) | CN102272599B (hr) |
| AU (1) | AU2009314141B2 (hr) |
| BR (1) | BRPI0921150B1 (hr) |
| CA (1) | CA2743305C (hr) |
| CY (1) | CY1118933T1 (hr) |
| DK (1) | DK2356462T3 (hr) |
| EA (1) | EA023466B1 (hr) |
| ES (1) | ES2623128T3 (hr) |
| HK (3) | HK1161350A1 (hr) |
| HR (1) | HRP20170463T1 (hr) |
| HU (1) | HUE032623T2 (hr) |
| IL (1) | IL212822A (hr) |
| LT (1) | LT2356462T (hr) |
| MX (2) | MX2011005007A (hr) |
| NZ (2) | NZ602369A (hr) |
| PL (1) | PL2356462T3 (hr) |
| PT (1) | PT2356462T (hr) |
| RS (1) | RS55784B1 (hr) |
| SG (1) | SG10201701954QA (hr) |
| SI (1) | SI2356462T1 (hr) |
| WO (1) | WO2010056753A1 (hr) |
| ZA (1) | ZA201103416B (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2356462T3 (en) | 2008-11-11 | 2017-02-27 | Univ Michigan Regents | ANTI-CXCR1 COMPOSITIONS AND PROCEDURES |
| GB201106870D0 (en) | 2011-04-26 | 2011-06-01 | Univ Belfast | Marker |
| ES2697674T3 (es) * | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
| CN103159649B (zh) * | 2011-12-19 | 2016-03-09 | 天津市国际生物医药联合研究院 | 磺酰胺类化合物的制备及其应用 |
| CN103159650B (zh) * | 2011-12-19 | 2016-04-20 | 天津市国际生物医药联合研究院 | 芳香杂环磺酰胺类化合物的制备及其应用 |
| US20150266961A1 (en) * | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
| ES2728305T3 (es) * | 2013-04-29 | 2019-10-23 | Ogd2 Pharma | Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas |
| JP6683986B2 (ja) * | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
| EP3518898A4 (en) | 2016-10-03 | 2020-06-17 | The Children's Medical Center Corporation | PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY |
| AU2017360887B2 (en) * | 2016-11-17 | 2023-01-19 | Nant Holdings Ip, Llc | Validation of inferred anticancer pathways |
| US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US10100275B2 (en) | 2017-03-16 | 2018-10-16 | King Faisal Specialist Hospital & Research Centre | Method for generating human multipotent mammary stem cells from normal primary breast luminal cells |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| RU2702910C2 (ru) * | 2018-12-20 | 2019-10-14 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения количества стволовых клеток рака молочной железы |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| RU2700695C2 (ru) * | 2019-02-27 | 2019-09-19 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ снижения клоногенной активности стволовых клеток рака молочной железы |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN113101362A (zh) * | 2020-01-10 | 2021-07-13 | 北京锐瑟生物医药科技发展有限公司 | 用于缓解癌症化疗引起抗药性并对化疗增效的医药组合物及其用途 |
| CN114075286A (zh) * | 2020-08-21 | 2022-02-22 | 张家港博泽利斯生物技术有限公司 | 一种抗人cxcr1蛋白单克隆抗体的制备方法 |
| WO2023032957A1 (ja) * | 2021-08-30 | 2023-03-09 | 学校法人東京薬科大学 | がんの予防および／または治療のための医薬組成物 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4109496A (en) | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
| US4323546A (en) | 1978-05-22 | 1982-04-06 | Nuc Med Inc. | Method and composition for cancer detection in humans |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US4981785A (en) | 1988-06-06 | 1991-01-01 | Ventrex Laboratories, Inc. | Apparatus and method for performing immunoassays |
| US4968103A (en) | 1988-07-22 | 1990-11-06 | Photofinish Cosmetics Inc. | Method of making a brush |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69326967T2 (de) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phasenmodulationsenergieübertragungsfluoroimmunassay |
| US5376313A (en) | 1992-03-27 | 1994-12-27 | Abbott Laboratories | Injection molding a plastic assay cuvette having low birefringence |
| EP0672131B1 (en) | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | A novel cell cycle control protein |
| US5876978A (en) | 1993-04-06 | 1999-03-02 | Medical College Of Ohio | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5643765A (en) | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5599677A (en) | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6156305A (en) | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2237589A1 (en) * | 1995-11-16 | 1997-05-22 | Michael W. Dahm | Method of quantifying tumour cells in a body fluid and a suitable test kit |
| JP2000502450A (ja) | 1995-12-22 | 2000-02-29 | アボツト・ラボラトリーズ | 蛍光偏光免疫アッセイによる診断法 |
| US5885529A (en) | 1996-06-28 | 1999-03-23 | Dpc Cirrus, Inc. | Automated immunoassay analyzer |
| WO1998016238A2 (en) | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
| CA2283267A1 (en) | 1997-03-07 | 1998-09-11 | Clare Chemical Research Llc | Fluorometric detection using visible light |
| US8044259B2 (en) * | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US20020147312A1 (en) * | 2001-02-02 | 2002-10-10 | O'keefe Theresa | Hybrid antibodies and uses thereof |
| JP2005511754A (ja) | 2001-12-07 | 2005-04-28 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 乳癌幹細胞の予測的同定および特徴づけ |
| US7919083B2 (en) * | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| ES2384622T3 (es) * | 2003-05-30 | 2012-07-10 | Agensys, Inc. | Variantes del antígeno de células madre de próstata (PSCA) y subsecuencias de las mismas |
| CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20050142136A1 (en) * | 2003-10-23 | 2005-06-30 | Lary Suva | Anti-interleukin 8 therapy for tumor osteolysis |
| WO2005074633A2 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| WO2005103711A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1) |
| JP2007537272A (ja) | 2004-05-12 | 2007-12-20 | シェーリング コーポレイション | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト |
| GB0417740D0 (en) * | 2004-08-10 | 2004-09-08 | Uc3 | Methods and kit for the prognosis of breast cancer |
| AU2006308847C1 (en) * | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| US20070208074A1 (en) * | 2006-01-24 | 2007-09-06 | Bonni Azad M | Methods and compositions for treating and preventing tumors |
| KR101376472B1 (ko) * | 2006-04-21 | 2014-03-19 | 글락소스미스클라인 엘엘씨 | Ｉｌ８ 수용체 길항제 |
| US20080187938A1 (en) * | 2006-09-22 | 2008-08-07 | The Regents Of The University Of Michigan | ALDH1 As A Cancer Stem Cell Marker |
| JP5311439B2 (ja) * | 2006-12-27 | 2013-10-09 | 日本メナード化粧品株式会社 | 皮膚の状態を評価する方法及びその用途 |
| CN101126758A (zh) * | 2007-09-06 | 2008-02-20 | 江苏省肿瘤医院 | 流式细胞术同步检测肿瘤中多种细胞蛋白表达的方法 |
| US20110111434A1 (en) | 2008-07-15 | 2011-05-12 | Huang Emina H | Colon stem cells associated with colitisand colorectal cancer and methods of use |
| DK2356462T3 (en) | 2008-11-11 | 2017-02-27 | Univ Michigan Regents | ANTI-CXCR1 COMPOSITIONS AND PROCEDURES |
-
2009
- 2009-11-11 DK DK09826676.0T patent/DK2356462T3/en active
- 2009-11-11 CN CN200980153571.6A patent/CN102272599B/zh active Active
- 2009-11-11 EP EP16200083.0A patent/EP3153862A1/en not_active Withdrawn
- 2009-11-11 MX MX2011005007A patent/MX2011005007A/es active IP Right Grant
- 2009-11-11 AU AU2009314141A patent/AU2009314141B2/en active Active
- 2009-11-11 JP JP2011535789A patent/JP5716180B2/ja active Active
- 2009-11-11 SI SI200931627A patent/SI2356462T1/sl unknown
- 2009-11-11 CN CN201410775973.2A patent/CN104623664B/zh active Active
- 2009-11-11 EA EA201100779A patent/EA023466B1/ru unknown
- 2009-11-11 KR KR1020157013977A patent/KR20150065930A/ko active IP Right Grant
- 2009-11-11 ES ES09826676.0T patent/ES2623128T3/es active Active
- 2009-11-11 PL PL09826676T patent/PL2356462T3/pl unknown
- 2009-11-11 KR KR1020147028842A patent/KR101588547B1/ko active IP Right Grant
- 2009-11-11 KR KR1020117013420A patent/KR20110093893A/ko active Application Filing
- 2009-11-11 EP EP09826676.0A patent/EP2356462B1/en active Active
- 2009-11-11 NZ NZ602369A patent/NZ602369A/en unknown
- 2009-11-11 RS RS20170301A patent/RS55784B1/sr unknown
- 2009-11-11 SG SG10201701954QA patent/SG10201701954QA/en unknown
- 2009-11-11 WO PCT/US2009/064041 patent/WO2010056753A1/en active Application Filing
- 2009-11-11 PT PT98266760T patent/PT2356462T/pt unknown
- 2009-11-11 LT LTEP09826676.0T patent/LT2356462T/lt unknown
- 2009-11-11 CN CN201410775991.0A patent/CN104634972B/zh active Active
- 2009-11-11 US US12/616,579 patent/US8940301B2/en active Active
- 2009-11-11 HU HUE09826676A patent/HUE032623T2/hu unknown
- 2009-11-11 BR BRPI0921150-0A patent/BRPI0921150B1/pt active IP Right Grant
- 2009-11-11 CA CA2743305A patent/CA2743305C/en active Active
- 2009-11-11 NZ NZ625440A patent/NZ625440A/en unknown
-
2011
- 2011-05-10 ZA ZA2011/03416A patent/ZA201103416B/en unknown
- 2011-05-11 IL IL212822A patent/IL212822A/en active IP Right Grant
- 2011-05-11 MX MX2015011045A patent/MX351889B/es unknown
-
2012
- 2012-02-24 HK HK12101909.4A patent/HK1161350A1/xx unknown
- 2012-02-24 HK HK15106856.3A patent/HK1206256A1/xx unknown
-
2013
- 2013-10-11 JP JP2013214161A patent/JP5909783B2/ja active Active
-
2014
- 2014-12-10 US US14/566,415 patent/US9606124B2/en active Active
- 2014-12-10 US US14/566,436 patent/US10557850B2/en active Active
-
2015
- 2015-07-20 HK HK15106853.6A patent/HK1206421A1/xx unknown
- 2015-11-16 JP JP2015223818A patent/JP2016065082A/ja not_active Withdrawn
-
2017
- 2017-03-21 HR HRP20170463TT patent/HRP20170463T1/hr unknown
- 2017-03-29 CY CY20171100385T patent/CY1118933T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170463T1 (hr) | Pripravci i postupci protiv cxcr1 | |
| De Vlieghere et al. | Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics | |
| PH12019501126A1 (en) | Bispecific antibodies binding to coagulation factor ix and ciagulation factor x | |
| Alexander et al. | DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer | |
| EP2592156A3 (en) | Gene expression markers of tumor resistance to HER2 inhibitor treatment | |
| WO2010009368A3 (en) | Compositions for the detection and treatment of colorectal cancer | |
| ATE492651T1 (de) | Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs | |
| PE20180798A1 (es) | Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3 | |
| ES2627909T3 (es) | Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos | |
| EA200970210A1 (ru) | Prlr-специфическое антитело и его применения | |
| EA201790986A1 (ru) | Антитела к cd73 и их применения | |
| MX2018002933A (es) | Pigmentos casi infrarrojos (nir) dirigidos por antígeno de membrana específico de próstata (psma) y sus usos. | |
| JP2009509171A5 (hr) | ||
| AR123542A2 (es) | Compuesto inhibidor de iap, método in vitro para inhibir la unión de una proteína iap con una proteína caspasa y método in vitro de sensibilización de una célula a una señal de apoptosis | |
| RU2014119426A (ru) | Способы применения антагонистов scd1 | |
| JP2014144959A5 (hr) | ||
| TN2011000524A1 (en) | Antibodies specific to cadherin -17 | |
| WO2007059190A3 (en) | Compositions of and methods of using stabilized psma dimers | |
| WO2010127417A3 (en) | Hepatocellular carcinoma | |
| Colleselli et al. | Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58: 12-8 | |
| EP2280078A4 (en) | MARKER FOR DETERMINING BREAST CANCER, TEST METHOD, AND TEST KIT | |
| CO6612254A2 (es) | Polopétidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas | |
| CY1124070T1 (el) | Igf-1r αντισωμα και χρηση αυτου για τη διαγνωση καρκινου | |
| FR2940087B1 (fr) | Erythrocytes contenant du facteur viii, preparation et utilisations. | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom |